Skip to search formSkip to main contentSkip to account menu

losoxantrone

Known as: 7-hydroxy-2(2-((2-hydroxyethyl) amino) ethyl)5-(2-((2-hydroxyethyl)amino)ethyl)amino anthra(1,9-cd)pyrazole-6(2H)-one 
An anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (3)

AnthraquinonesAntineoplastic AgentsPyrazolones

Narrower (3)

BiantrazoleCI 941DuP 941
Losoxantrone HydrochlorideNSC 357885anthrapyrazolonecyclophosphamide/losoxantrone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
The oxidative biotransformation of losoxantrone (CI-941).
The oxidative biotransformation of the anticancer drug 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino… 
Review
2001
Review
2001
Separation methods for anthraquinone related anti-cancer drugs.
2001
2001
DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.
The physicochemical and DNA-binding properties of anticancer 9-aza-anthrapyrazoles (9-aza-APs) were investigated and compared… 
2000
2000
A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
Our purpose in this study was to determine the efficacy and toxicity of losoxantrone (DuP-941), an anthrapyrazole, in patients… 
1999
1999
Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone.
Review
1999
Review
1999
Monotherapy of metastatic breast cancer: a review of newer agents.
PURPOSE New agents for the palliative treatment of metastatic breast cancer have emerged in the 1990s. This review summarizes the… 
1999
1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
A Phase I and pharmacological study was performed to evaluate the feasibility, maximum tolerated dose (MTD), dose-limiting… 
1996
1996
Validation of cleaning procedures for highly potent drugs. I. Losoxantrone.
The validation of a procedure designed to clean glass and stainless steel surfaces after exposure to the experimental anticancer… 
Highly Cited
1994
Highly Cited
1994
Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
BACKGROUND The cumulative cardiotoxicity of anthracyclines is thought to result from the generation of free radicals. New DNA… 
Review
1994
Review
1994
New chemotherapeutic agents for breast cancer
The drug discovery programs of the National Cancer Institute and the pharmaceutical industry recently have provided oncologists… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)